SCHEMBL21436088

SCHEMBL21436088

CC(C)Oc1ccc(-n2cnc3ccc(Br)cc32)cc1.CN(C)c1ccc(B(O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.43
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPK10 P53779 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
ATM Q13315 3/20 0.36
SIK1 P57059 2/20 0.35
SIK2 Q9H0K1 2/20 0.35
SIK3 Q9Y2K2 2/20 0.35
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MCL1 Q07820 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21436091 0.89 ALDH1A1 (0.47) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL21436069 0.86 FGFR1 (0.43) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL19781251 0.84 FGFR1 (0.58) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL21436077 0.84 RAB9A (0.42) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL21436080 0.81 GABRP (0.44) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL19781569 0.80 FGFR1 (0.51) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL15213070 0.76 FGFR1 (0.67) FGFR1ALDH1A1HTTSIK1SIK2
SCHEMBL21436075 0.74 ALDH1A1 (0.46) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL21436072 0.74 HPGD (0.48) FGFR1ALDH1A1HTTHPGDMAPK1
SCHEMBL21436076 0.73 RAB9A (0.50) FGFR1ALDH1A1HTTHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S FGFR1 3928/4885ALDH1A1 1146/4885HTT 1337/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S FGFR1 3928/4885ALDH1A1 1146/4885HTT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.